RI
Therapeutic Areas
Cytokinetics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MYQORZO (aficamten) | Obstructive Hypertrophic Cardiomyopathy (oHCM) | Commercial |
| Aficamten | oHCM (Monotherapy vs. Standard of Care) | Phase 3 |
| Omecamtiv Mecarbil | Heart Failure with Reduced Ejection Fraction (HFrEF) | Phase 3 |
| Ulacamten (CK-586) | Heart Failure with Preserved Ejection Fraction (HFpEF) with Hypercontractility | Phase 2 |
| CK-136 | Heart Failure | Phase 1 |
| Reldesemtiv | Amyotrophic Lateral Sclerosis (ALS) | Phase 3 |
| CK-089 | Neuromuscular Disease | Phase 1 |
| Additional skeletal muscle activators | Neuromuscular Diseases | Research/Preclinical |